Logo
Media
Media

Media

Rigontec Starts First-In-Human, Phase I/II Trial of RIG-I Agonist RGT100 and Appoints Eugen Leo as Chief Medical Officer

Munich, Germany and Cambridge, MA, May 3, 2017 – Rigontec, the leader in RIG-I targeting RNA therapeutics, today announced the dosing of the first patient in a phase I/II study with intratumoral/intralesional administration of its lead compound RGT100 in solid tumors and lymphoma. RGT100 targets t...

Continue reading ...